Advance in Treatment of Uveal Melanoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 June 2025 | Viewed by 944
Special Issue Editors
Interests: uveal melanoma; metastases; treatment
Special Issues, Collections and Topics in MDPI journals
Interests: ophthalmic epidemiology; public health; ocular oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Uveal melanoma (UM) is adults' most common primary intraocular tumor. The biology and immunology of UM significantly differ from cutaneous melanoma, which requires separate research efforts to elucidate treatment opportunities. Intraocular tumor is currently successfully treated mainly with radiotherapy, such as brachytherapy or proton beam. Surgical methods can also be used, including egzo or endo-resection, and enucleation in the case of some advanced stages. Despite effective local treatment, it is associated with death in approximately 50% of patients due to metastatic disease. Metastases are mainly to the liver and other organs. We do not yet have effective methods of treating uveal melanoma metastases. Different characteristics of metastases require the development of treatment approaches, continuous use for optimal targeted therapy, and immunotherapy in adjuvant and metastatic settings. Understanding the biological mechanisms of UM development and metastatic spread will help to develop new possibilities for treating metastatic uveal melanoma in genetically and immunologically different groups of patients. The series of articles will be devoted to current data on the biology of UM, immunological, and genetic aspects that influence local treatment and treatment strategies for metastatic disease.
Prof. Dr. Bożena Romanowska-Dixon
Dr. Michał S. Nowak
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- uveal melanoma
- distant metastases
- treatment modalities
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
